Welcome to our dedicated page for Smith & Nephew news (Ticker: SNN), a resource for investors and traders seeking the latest updates and insights on Smith & Nephew stock.
Smith & Nephew plc reports news as a global medical technology company focused on the repair, regeneration and replacement of soft and hard tissue. Coverage centers on Orthopaedics, Sports Medicine & ENT and Advanced Wound Management, including wound dressings, negative pressure wound therapy, cartilage and rotator cuff repair implants, orthopedic reconstruction, trauma and extremities products, and surgical robotics.
Recurring developments include product launches and clinical evidence for ALLEVYN COMPLETE CARE, RENASYS EDGE, CARTIHEAL AGILI-C, REGENETEN, CORI, AETOS and related platforms; conference showcases; distribution agreements; segment performance updates; share buybacks; and governance matters tied to the company’s London-listed shares and NYSE-traded ADRs.
Smith+Nephew (NYSE:SNN) has launched the WOUND COMPASS™ Clinical Support App, aimed at assisting healthcare professionals in wound assessment and decision-making. The app addresses practice variation, which negatively affects patient outcomes in chronic wound care. Validated by over 70 clinicians, it enhances nurse confidence in assessments, with 83% of non-specialists reporting it simplifies evaluations. Available on both Apple and Android, the app categorizes wounds and offers tailored treatment guidance. This innovation is part of Smith+Nephew’s commitment to improving patient care and outcomes.
Smith+Nephew (NYSE: SNN) successfully performed its first robotic-assisted surgery using the LEGION CONCELOC Cementless Total Knee System. Conducted by Dr. Cyna Khalily in Louisville, KY, this milestone enhances its portfolio of cementless knee implants and robotic technology. The procedure employs the CORI Surgical System, designed to optimize surgical efficiency by eliminating preoperative CT imaging, thus reducing costs and radiation exposure. This innovation reflects Smith+Nephew's commitment to improving surgical outcomes and employing advanced materials for knee arthroplasty.
Smith+Nephew (LSE: SN, NYSE: SNN) published a peer-reviewed article in Wounds International predicting a potential release of 3.5 billion hours of nursing time by 2030 through shared care in chronic wound management and the use of long-wear advanced foam dressings. The study highlights a global nursing shortage of 10.6 million by 2030, emphasizing the need for efficient care practices. The implementation of shared care practices could lead to an annual reallocation of over 433 million hours of clinical nursing time worldwide, enhancing patient care and optimizing resources.
Smith+Nephew (NYSE:SNN) announced the successful first total hip arthroplasty (THA) using its RI.HIP MODELER at Duke Regional Hospital. The procedure was performed by Dr. Rhett Hallows, who utilized the preoperative spinopelvic assessment tool to enhance surgical planning. In April, Dr. Thorsten Seyler executed the inaugural RI.HIP NAVIGATION procedure on the CORI Surgical System. This system aids in precise component alignment, addressing challenges in hip surgery. The innovations are expected to drive growth for the CORI Surgical System.
Healiva® announced its acquisition of two innovative cell therapy assets from Smith+Nephew (NYSE:SNN), enhancing its portfolio of chronic wound care solutions. The first asset, EpiDex®, is an autologous epidermal equivalent that facilitates surgery-free healing for chronic venous leg ulcers (VLUs), while the second, healiva®002, is an allogeneic cell therapy proven effective for hard-to-treat VLUs. This acquisition aims to expedite market launch and addresses the urgent need for effective treatments for the 36 million people suffering from chronic wounds worldwide.
Smith+Nephew (LSE: SN, NYSE: SNN) announced a peer-reviewed study published in the Advances in Wound Care Journal, demonstrating that GRAFIX Cryopreserved Placental Membrane significantly cuts diabetic foot ulcer (DFU) recurrence rates. The study analyzed over 1.3 million Medicare patients and showed a reduction of up to 58.5% in ulcer recurrence at 365 days compared to competitors. With Medicare patients spending an estimated $6-18 billion annually on DFU treatment, GRAFIX has gained coverage from Medicare and major payers, reinforcing its potential financial advantage.
Smith+Nephew (NYSE:SNN) will showcase its innovations in Orthopaedic Reconstruction and Robotics at the AAOS 2022 Annual Meeting in Chicago. The highlight is the launch of the LEGION CONCELOC Cementless Total Knee System, marking Smith+Nephew as the only U.S. company with a complete cementless knee portfolio. Their ABLE Advanced Anterior Approach for Total Hip Arthroplasty is also noteworthy for its efficiency and low complication rates. The CORI Surgical System, offering expanded indications in orthopedic procedures, will also be presented, enhancing Smith+Nephew's robotic-assisted surgery capabilities.
Smith+Nephew (LSE:SN, NYSE:SNN) announced the showcase of its latest Sports Medicine innovations at the American Academy of Orthopaedic Surgeons 2022 Annual Meeting in Chicago, IL. Key products include the FAST-FIX™ FLEX Meniscal Repair System, which enhances meniscus repair opportunities, and the INTELLIO™ Connected Tower, which integrates surgical technologies for improved workflow. Other innovations include the WEREWOLF™ FASTSEAL 6.0 Hemostasis Wand and REGENETEN™ Bioinductive Implant, aimed at better patient outcomes and efficiency in joint surgeries.
Smith+Nephew (LSE: SN, NYSE: SNN) has launched the OXINIUM Technology Tour of Change, a 550-square-foot mobile exhibit covering 20 U.S. cities over 12 weeks. This initiative showcases OXINIUM Technology, recognized for its low revision risk in total hip arthroplasty, with over two million clinical cases. The exhibit aims to educate healthcare professionals on the unique manufacturing of OXINIUM, emphasizing its durability, wear resistance, and absence of harmful nickel, cobalt, and chromium. The tour also highlights OXINIUM's integration with Smith+Nephew's Real Intelligence platform.
Smith+Nephew (NYSE:SNN) announced the successful completion of the first surgery using its JOURNEY II Medial Dished (MD) System for total knee arthroplasty (TKA). Performed by Dr. Ran Schwarzkopf at NYU Langone Health, this innovative system enhances knee kinematics and stability. The JOURNEY II MD aims to improve patient outcomes and satisfaction by replicating natural motion in knee replacements. The product is now available in the United States, following customer demand for medial dished inserts that expand clinical applications of the JOURNEY II Knee System.